ImageneBio Appoints New CFO; CMO to Transition to Consultant

What Happened

• ImageneBio announced that, effective July 20, 2026, Yanina Grant‑Huerta was appointed Chief Financial Officer, principal financial officer and principal accounting officer, based in part on the recommendation of CEO Kristin Yarema (who had been interim principal financial officer). Ms. Grant‑Huerta, age 49, joins from Atara Biotherapeutics where she served most recently as Chief Accounting Officer (Mar 2025–Jul 2026) and previously spent 14 years at Amgen.
• The company also disclosed that Chief Medical Officer Benjamin Porter‑Brown will transition from his full‑time CMO role to a consulting clinical development and strategic advisor role effective July 24, 2026.

Key Details

• Base salary: $450,000 per year for Ms. Grant‑Huerta; annual discretionary bonus target of 40% of base salary.
• Equity inducements: RSU grant of 65,000 shares (25% vest at 1 year, then 1/12th quarterly); option to purchase 95,000 shares (25% vest at 1 year, then 1/36th monthly); option exercise price = closing stock price on grant date.
• Severance/Change in control: participation agreement gives C‑suite (non‑CEO) covered‑termination benefits — if termination occurs during a change‑in‑control period: lump sum = 12 months base salary + 100% of target bonus, up to 12 months continued health coverage, and full accelerated vesting of equity; if outside a change‑in‑control period: continued base salary payments for 12 months and up to 12 months continued health coverage. Severance is subject to execution of a release and compliance with confidentiality/IP agreements.

Why It Matters

• A permanent CFO with senior finance and accounting experience at biopharma companies (Atara, Amgen) replaces an interim arrangement, which can provide financial leadership and continuity for investors monitoring operations, budgeting and reporting.
• The compensation and equity awards are typical for executive hires but will create future expense and potential stock dilution as awards vest or options are exercised.
• The CMO’s move to a consulting role signals continuity in clinical strategy while reducing his full‑time responsibilities; investors should watch future disclosures about any changes to clinical leadership or development plans.